FDA Approved: ORIAHNN — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA supplemental application for ORIAHNN (elagolix with estradiol and norethindrone) from AbbVie Inc. seeks a label update. The target condition includes uterin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menorrhagia
• Uterine Fibroids

Drugs mentioned

• ORIAHNN (ELAGOLIX AND ESTRADIOL AND NORETHISTERONE)

Snippet

SUPPL AP for ORIAHNN (ELAGOLIX AND ESTRADIOL AND NORETHISTERONE)